CJC-1295 is not merely "not approved"
In mouse models of highfat dietinduced liver steatosis, it significantly inhibits hepatic NNMT activity, reduces NAM methylation, increases NAD+ and SAM levels, enhances mitochondrial fatty acid oxidation, reduces hepatic triglyceride and lipid accumulation, lowers lipotoxicity markers (e.g., malondialdehyde, transaminases), improves hepatocellular injury, and reverses steatosis
We also acknowledge the Einstein Computational Genomic Core for its support, and the NCI supported Einstein Cancer Center (P30CA013330)
Where MIC Fits Now That GLP-1s Exist This is the question that has changed the category, and any guidance written before 2024 simply does not address it
This rapidly growing field is continuously uncovering new therapeutic peptides designed to target specific diseases and conditions, offering hope for more personalized and effective treatments